patients were referred to the National University Hospital, Singapore for consideration of LT for HCC. Sixty-five patients (33.8%) were found suitable for transplant and were placed on the waitlist. Analysis was performed in these patients.
INTRODUCTION
and/or Radiofrequency Ablation (RFA) to prevent patients from progressing beyond criteria while they await an organ. This paper aims to study the role of BT in patients with HCC needing LT.
MATERIALS AND METHODS
In Singapore, LT is one of the accepted modalities for the treatment of HCC, and since 2007, the UCSF Criteria for LT for HCC has been adopted for the purpose of organ allocation (prior to that, the Milan criteria was adopted). HCC is usually treated using a multimodality ap- Guidelines (Version 1.1). 4 In patients who had received multiple BT, RECIST criteria were determined by comparing imaging performed at listing and that performed just prior to the transplant or at the time when they were removed from the waitlist. Those who completed the LT workup and were found to be suitable for LT were included in the study.
Transplanted patients were followed up for a minimum period of 3 years to assess long-term oncological outcomes. The remaining 65 patients were placed on the national waitlist for LT and were included in our study. Flowchart for referral and study inclusion is appended in Fig. 1 .
Baseline patient demographics and disease characteristics were comparable between the two groups and are detailed in Table 1 . Given the multi-modality approach to the management of HCC, patients could be treated with RFA, TACE, PEI or a combination of these treatments prior to LT. Data regarding the various prelisting treatments re- ceived by patients are presented in Table 2 . In our cohort, the overall dropout rate at 6 months was 18.4%, while the dropout rate due to tumor progression beyond criteria was 6.2%. The percentage rose to 29.2% and 12.3%, respectively at 12 months. Subgroup analysis did not reveal any significant difference in dropout rates 
Clinical outcomes

DISCUSSION
HCC is currently being treated with use of a multimodality approach. While LT for a selected group of patients has been proven to provide the best outcome, the role of BT in waitlisted patients with HCC remains controversial. [6] [7] [8] The theoretical advantages of BT in patients with HCC on the waitlist are multifold. Firstly, proponents of BT believe that it will reduce dropout rates due to tumor progression beyond criteria. [9] [10] [11] Secondly, they also propose that by reducing tumor burden, it may improve post-transplant oncological results including lower tumor recurrence rates. [12] [13] [14] Lastly, BT can play a role in identifying candidates with poor tumor biology who might not be ideal candidates for LT. [15] [16] [17] [18] When LT began to be performed more widely as a definitive treatment for patients with HCC, there was also a concurrent increase in the number of patients with active HCC on the waitlist. A significant proportion of patients subsequently dropped out of the waitlist due to progression of tumor beyond criteria. In 1999, Llovet et al. 19 reported a dropout rate of 23% within 6 months without BT for patients with HCC on the waitlist. Since then, Ashoori et al. 20 reported dropout rates of 2.8% and 5.5% could not make recommendations with respect to the use of BT in UNOS T1 tumors, or with respect to the use of one type of BT over another due to a lack of evidence. 28 The group recommended that BT may be appropriate in patients with UNOS T2 tumors with an expected wait time of more than 6 months. In a clinical setting, with often unpredictable wait times, BT has been widely adopted.
The current evidence shows that ablative techniques achieved higher rates of complete necrosis in lesions less than 3 cm, compared to TACE, 10,29 complete necrosis being a strong marker for long term survival. Agopian showed in 501 consecutive patients that a complete pathological response to BT strongly predicted long term tumor-free survival, with 5 year disease specific survival of 87%. 30 Kornberg et al. 31 obtained similar results in their study, 40 However, more recent papers have shown that recurrence rates are not increased after LDLT. 41 The topic continues to cause controversy, with two meta-analysis, by Liang et al. 42 in 2012 and Grant et al. 43 in 2013 deriving conflicting conclusions. The low frequency of recurrence in our cohort makes analysis between DDLT and LDLT difficult. In the same study by Kulik mentioned above, despite having more advanced tumours in the LDLT cohort, patients were less likely to receive BT, and they received a reduced number of BT when rendered, leaving observers unable to assess the tumor response to BT. 39 This has led to suggestions such as an "ablate and wait" strategy, or even a "bridge and wait" strategy to fully assess tumor biology prior to LT. 44 Further studies are required to assess the role of BT in such a setting.
In our cohort, none of our patients who underwent LDLT received BT. Despite the possible increased recurrence rates, the scarcity of deceased donor organs and the ever expanding waitlist necessitates the use of LDLT to augment the pool of donor organs. We suggest that all patients placed on the national waitlist should explore the option of LDLT.
In conclusion, BT remains controversial in the management of patients with HCC on the waitlist. Our study did not show any evidence regarding the use of BT to reduce dropout rates or improvement of oncological outcomes; however, we were able to maintain our group of patients on the waitlist for longer periods of time with selective use of BT. We advocate selective use of BT in patients who are at low risk for hepatic decompensation, in those who are at risk for progressing beyond criteria, and in those who will remain on the waitlist for a period of more than 6 months. Also, all patients who are listed should be counseled for possible LDLT.
